A detailed history of Concurrent Investment Advisors, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Concurrent Investment Advisors, LLC holds 23,909 shares of EXEL stock, worth $995,809. This represents 0.02% of its overall portfolio holdings.

Number of Shares
23,909
Previous 18,726 27.68%
Holding current value
$995,809
Previous $825 Million 19.64%
% of portfolio
0.02%
Previous 0.02%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 27, 2025

BUY
$36.22 - $46.25 $187,728 - $239,713
5,183 Added 27.68%
23,909 $987 Million
Q2 2025

Jul 25, 2025

BUY
$34.13 - $46.26 $216,520 - $293,473
6,344 Added 51.24%
18,726 $825 Million
Q1 2025

Apr 29, 2025

BUY
$32.38 - $39.16 $400,929 - $484,879
12,382 New
12,382 $457 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $13.4B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Concurrent Investment Advisors, LLC Portfolio

Follow Concurrent Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concurrent Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Concurrent Investment Advisors, LLC with notifications on news.